Published by Iain Gilbert on 15th February 2024
(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker GSK from £16.50 to £18.20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of its patent on HIV drug dolutegravir.
URL: http://www.digitallook.com/dl/news/story/34092334/...